BIO-RAD LABORATORIES, INC. Financials Bio-Rad Laboratories, Inc.
Equities
BIO
US0905722072
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 289.4 USD | -0.83% |
|
-1.55% | -10.36% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 11,075 | 17,345 | 22,439 | 12,460 | 9,399 | 8,265 | - | - |
| Enterprise Value (EV) 1 | 10,400 | 17,345 | 22,439 | 11,868 | 8,992 | 7,591 | 7,437 | 7,225 |
| P/E ratio | - | 4.62 x | 5.38 x | - | -14.8 x | 28.3 x | 29.2 x | 25.6 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 4.79 x | 6.81 x | 7.68 x | 4.45 x | 3.52 x | 3.11 x | 2.96 x | 2.87 x |
| EV / Revenue | 4.5 x | 6.81 x | 7.68 x | 4.24 x | 3.37 x | 2.85 x | 2.66 x | 2.51 x |
| EV / EBITDA | 26.7 x | 32.3 x | 33.1 x | 17.8 x | 16.8 x | 16.1 x | 14.2 x | 13 x |
| EV / FCF | 28,939,110 x | 36,407,140 x | 41,886,472 x | 126,657,378 x | 23,981,479 x | - | - | - |
| FCF Yield | 0% | 0% | 0% | 0% | 0% | - | - | - |
| Price to Book | - | - | - | 1.27 x | 1.05 x | 0.89 x | 0.86 x | 0.82 x |
| Nbr of stocks (in thousands) | 29,935 | 29,831 | 29,918 | 29,824 | 29,145 | 28,525 | - | - |
| Reference price 2 | 370.0 | 582.9 | 755.6 | 420.5 | 322.9 | 291.9 | 291.9 | 291.9 |
| Announcement Date | 2/13/20 | 2/11/21 | 2/10/22 | 2/16/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,312 | 2,546 | 2,923 | 2,802 | 2,671 | 2,661 | 2,794 | 2,877 |
| EBITDA 1 | 389.6 | 537.4 | 677.5 | 667.9 | 535.9 | 470.2 | 522.6 | 555.2 |
| EBIT 1 | 278.5 | 426.6 | 571.2 | 524 | 378.9 | 347 | 394.4 | 434 |
| Operating Margin | 12.05% | 16.76% | 19.54% | 18.7% | 14.19% | 13.04% | 14.11% | 15.08% |
| Earnings before Tax (EBT) 1 | - | 4,908 | 5,438 | - | -850.1 | 376.5 | 366 | 423 |
| Net income 1 | - | 3,806 | 4,246 | -3,628 | -637.3 | 294 | 285 | 326 |
| Net margin | - | 149.52% | 145.28% | -129.45% | -23.86% | 11.05% | 10.2% | 11.33% |
| EPS 2 | - | 126.2 | 140.6 | - | -21.82 | 10.30 | 10.01 | 11.42 |
| Free Cash Flow | 359.4 | 476.4 | 535.7 | 93.7 | 374.9 | - | - | - |
| FCF margin | 15.55% | 18.71% | 18.33% | 3.34% | 14.04% | - | - | - |
| FCF Conversion (EBITDA) | 92.24% | 88.64% | 79.08% | 14.03% | 69.97% | - | - | - |
| FCF Conversion (Net income) | - | 12.52% | 12.62% | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/13/20 | 2/11/21 | 2/10/22 | 2/16/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 732.8 | 700.1 | 691.1 | 680.8 | 730.3 | 676.8 | 681.1 | 632.1 | 681.2 | 610.8 | 640.8 | 669.4 | 733.2 | 649.3 | 675.8 |
| EBITDA 1 | 140 | 179.5 | 156.2 | 132.3 | 156.5 | 148.5 | 137.9 | 112.7 | 136.8 | 108.5 | 93 | 119.1 | 154.6 | 114.1 | 121.5 |
| EBIT 1 | 112.8 | 153.8 | 129.9 | 105.8 | 127 | 84.17 | 107.9 | 81.59 | 105.2 | 59.01 | 64.91 | 88.84 | 121.9 | 82.69 | 91.17 |
| Operating Margin | 15.39% | 21.97% | 18.79% | 15.54% | 17.4% | 12.44% | 15.85% | 12.91% | 15.45% | 9.66% | 10.13% | 13.27% | 16.63% | 12.73% | 13.49% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | -1,500 | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | 827.7 | - | -1,162 | - | 349.7 | - | - | - | - | - | - |
| Net margin | - | - | - | - | 113.34% | - | -170.64% | - | 51.34% | - | - | - | - | - | - |
| EPS | - | - | - | -5.520 | - | - | -39.59 | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/10/22 | 4/28/22 | 7/28/22 | 10/27/22 | 2/16/23 | 5/4/23 | 8/3/23 | 10/26/23 | 2/15/24 | 5/7/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 675 | - | - | 592 | 408 | 674 | 828 | 1,040 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | 359 | 476 | 536 | 93.7 | 375 | - | - | - |
| ROE (net income / shareholders' equity) | - | 48.7% | 36.1% | 3.71% | 3.76% | 3.18% | 3.11% | 3.57% |
| ROA (Net income/ Total Assets) | - | 36.3% | 27.6% | - | - | 2.3% | 2.2% | 2.4% |
| Assets 1 | - | 10,491 | 15,374 | - | - | 12,783 | 12,955 | 13,583 |
| Book Value Per Share 2 | - | - | - | 332.0 | 307.0 | 327.0 | 340.0 | 354.0 |
| Cash Flow per Share | - | - | - | 6.530 | - | - | - | - |
| Capex 1 | 98.5 | 98.9 | 121 | 101 | - | 138 | 144 | 142 |
| Capex / Sales | 4.26% | 3.89% | 4.13% | 3.6% | - | 5.19% | 5.15% | 4.95% |
| Announcement Date | 2/13/20 | 2/11/21 | 2/10/22 | 2/16/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
291.9
USD
Average target price
393.8
USD
Spread / Average Target
+34.92%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.36% | 8.27B | |
| -6.46% | 180B | |
| +3.39% | 112B | |
| -3.68% | 68.53B | |
| +5.44% | 51.97B | |
| +5.70% | 44.08B | |
| +5.62% | 42.23B | |
| +25.42% | 32.43B | |
| +16.72% | 26.39B | |
| -4.29% | 24.97B |
- Stock Market
- Equities
- BIO Stock
- Financials Bio-Rad Laboratories, Inc.
